The word that matters most on this page is in VelaShape's own FDA clearance, and it is "temporary". K122579 was cleared on 13 September 2012. It covers relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation, temporary reduction in the appearance of cellulite, and temporary reduction of thighs circumferences. Temporary is not a caveat someone added later. It is the cleared wording.
VelaShape is also not cleared to destroy fat. Its body claim is a circumference claim on the thighs, which is a tape measure around a leg, plus the appearance of cellulite. CoolSculpting's claim is cold-assisted lipolysis, meaning breakdown of fat, in seven named body regions plus under the chin and jaw. Those are different claims, measured in different ways. Neither is a claim about your weight.
The machine combines four things at once: bipolar radiofrequency, infrared light, vacuum suction and mechanical massage. That mix is why the same device carries a circulation claim, a muscle-ache claim and a cellulite claim alongside the circumference one.
Published evidence for VelaShape exists, but it is thin. Two studies from 2009 describe this combination of radiofrequency, infrared, vacuum and massage. They cover arm, abdominal and flank fat, and loose skin. Their sample sizes, designs and funding could not be established, so no numbers from them are quoted here. There is no large, controlled, independent trial to point you to.
It was cleared as K122579 on 13 September 2012. Its product code is defined by the FDA around temporarily altering the appearance of cellulite. An earlier VelaShape clearance from 22 August 2007 exists, but its indication document could not be retrieved. A 510(k) clearance is a finding that a device is much the same as an existing one. It is not proof it works.
It was authorised through De Novo request DEN090002, decided 24 August 2010. That request created the FDA category for cryolipolysis.
Radiofrequency warms tissue between the poles. Infrared warms the layers nearer the surface. Vacuum and rollers lift and squeeze the skin and the fat under it.
Fat cells are more easily harmed by cold than skin, nerve and vessel. The cleared settings are specific: minus 10 degrees Celsius for 60 minutes under the chin, and minus 11 degrees for 35 minutes on the upper arm. The immune system clears the cells over the following weeks.
That is the entire indication, word for word. Note that the only body-shape claim is circumference of the thighs, and that it is marked temporary. There is no lipolysis or fat-destruction wording anywhere in it.
Submental and submandibular areas are cleared separately, up to a body mass index of 46.2. CoolSculpting Elite is K212707, cleared 5 November 2021. Nothing in that wording is described as temporary.
There is no large controlled independent trial of VelaShape to point to.
Single studies ranged from 10.3% to 25.5%. An independent randomised split-body trial in 2023 measured about 14%. A 2022 systematic review found that only 5 of 381 screened articles survived a formal check for bias.
Tape measurement moves with posture, breath, tape tension, time of day, meals and fluid. Nobody in this literature has published the measurement's own margin of error. That makes small circumference changes hard to read.
That main endpoint asks whether reviewers can pick out the "before" photograph better than chance, with a pass mark of 80%. The pivotal under-chin study, run by the manufacturer, reached 91%. It is a spot-the-difference test, not a measurement of fat.
Delayed pain is common. A review of 554 procedures found it ran 3 to 11 days and settled on its own. It happened most often in younger women treated on the abdomen.
That protocol comes from clinic sources, not from a maker or FDA document.
The mean was 5.6 cycles and 1.9 sessions. Results in the FDA-reviewed trials were checked at 12 or 16 weeks.
Nothing citable exists from a professional society or a consumer aggregate. Any range quoted is one clinic's own pricing.
Those reviewers rated it 59% "Worth It". The American Society of Plastic Surgeons' last published average physician fee for non-surgical fat reduction was $1,157, for 2023. That is a category average across six unrelated products, not a CoolSculpting price. No such fee appears in the 2024 report.
Most people read a cleared indication as a promise of a result. It is not. A 510(k) clearance only establishes that a device is much the same as something already on the market. But when a maker writes a qualifier into its own indication, and the FDA clears it that way, the qualifier is worth reading closely.
"Temporary reduction of thighs circumferences" tells you two things at once: The change is a measurement around a leg. And it does not stay. No duration is attached. The clearance does not say how long temporary is, and no published follow-up for VelaShape could be found to fill that in. So the honest position is this: the wording tells you the effect fades, and nobody has published how quickly.
This is not unique to VelaShape, and the contrast within the field is worth seeing. Some cleared devices carry very specific durability language. One cellulite device is cleared with wording that points to clinical data showing no real drop in benefit through five years of observation. Another is cleared for temporary improvement, supported by data through three months. All of that sits in the FDA-cleared text. Clinic pages routinely present devices as equal when their own clearances say otherwise.
These get treated as interchangeable, and they are four separate things. There is the distance around a limb. There is the thickness of the fat layer under the skin. There is the volume of a bulge. And there is what you weigh. Different devices are cleared and measured on different ones.
VelaShape's body claim is circumference: That is a tape measure. The number moves with posture, with which breath you are on, and with how tightly the tape is pulled. It also moves with the time of day, and with what you have eaten and drunk. Nobody in this literature has published how much a thigh circumference measurement varies for reasons that have nothing to do with treatment. That makes a small reduction genuinely hard to read.
CoolSculpting's claim is lipolysis, and the number underneath it is fat-layer thickness by ultrasound: In the better-documented studies that runs to two or three millimetres. Ultrasound of fat under the skin is fairly reliable when the protocol is standardised, though this literature rarely reports one. The noise floor from hydration alone is close to a millimetre.
Neither is weight: A pooled meta-analysis of cryolipolysis found no real weight change at all.
VelaShape's indication includes temporary reduction in the appearance of cellulite. Zeltiq's earlier skin-cooling clearance from 2009 - a different device from the fat-freezing one, with no fat claim in it - carried a minor claim for "temporary reduction in the appearance of cellulite" using an optional massage function. That is not part of the cryolipolysis indication, and it is worth not confusing the two.
Neither is a cellulite treatment in the sense most people mean. Cellulite comes from fibrous bands tying the skin down to deeper tissue. Published reviews of the anatomy conclude that approaches aimed at those bands are the ones producing lasting change. Approaches aimed at fat, or at the deeper skin layer, give patchy and short-lived results. Both of those reviews carry industry ties worth knowing about. Authors on one were investigators in a maker's cellulite drug programme, and the other came from a sponsored roundtable. Their conclusion is consistent, and it matches how the FDA structures its own clearances. Those list improving the appearance of cellulite as a separate purpose from reducing small areas of fat.
The FDA states it on its own body-contouring page, last updated 15 October 2025. Non-invasive body contouring "does not treat obesity or improve your health. It will not result in weight loss." CoolSculpting's maker safety document says the same in its own words. The body mass index numbers written into the clearance are limits on who may be treated. They are not something the treatment is meant to shift. No professional society has published a formal position statement to this effect. The regulator and the maker are the sources, and between them they are enough.
Disclose a pacemaker, implanted defibrillator or any metal or electronic implant near the area before a radiofrequency treatment: These are labelled exclusions for radiofrequency devices in general. They are set as a precaution rather than tested, so the team managing the implant are the right people to advise you.
For cryolipolysis, three cold-related blood disorders rule it out completely: They are cryoglobulinemia, cold agglutinin disease and paroxysmal cold hemoglobinuria. They read as unrelated jargon, but they share one logic: blood that behaves abnormally when it gets cold.
Raise any hernia at or near the site, including a repaired one: Hernia appears in the FDA's class-wide risk list and in CoolSculpting's own precautions. It is the item most often passed over.
Ask what the plan is after the first course: For a device whose clearance says temporary, the maintenance schedule and its cost are part of the price. It is easier to work that out before you start than after.
Also disclose: cold urticaria, Raynaud's or chilblains, reduced feeling or circulation in the area, bleeding disorders or blood thinners, recent surgery or scarring at the site, and eczema or dermatitis over the treatment area.
Fever or chills after treatment
Redness spreading outward from the treated area hour by hour
Pus or discharge from treated skin
These suggest a spreading infection and need urgent care the same day.
A firm, well-defined lump appears in a CoolSculpting-treated area two to six months later, above all if its shape matches the applicator. This is paradoxical adipose hyperplasia. It does not clear up on its own, and further cryolipolysis to the same area has been reported to make it worse
Pain or swelling is rising after day three rather than settling
Numbness in a treated area is still there past about three months
A burn, blister or open area appears - acute skin damage, dyspigmentation, infection and scarring are among the events reported for devices in this class in the FDA's adverse event database, which is voluntary and has no denominator
The treated skin darkens a lot over the weeks afterwards
The area looks hollow or dented next to the untreated side